Oren Gilad, President, CEO at Aprea Therapeutics, Inc. (APRE), bought 2,000 shares at $7.29 ($15K) on 2024-03-13, disclosed to the SEC on 2024-03-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| APRE | BUY | 2024-10-24 | $2K | — | Filing → |
| APRE | BUY | 2024-10-16 | $725 | — | Filing → |
| APRE | BUY | 2024-10-15 | $3K | — | Filing → |